Treatment proven to demonstrate significant survival improvement in patients with mCRC whose disease has progressed despite treatment with oxaliplatin-based regimen2 Sanofi and Regeneron Pharmaceuticals, Inc. announced today that they have launched ZALTRAP (aflibercept) which is licensed for use in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy for the treatment of adults with mCRC that is resistant to or has progressed after an oxaliplatin-based regimen.1Â?Colorectal cancer is the second most common cause of cancer death in the UK...
More...
More...